Group Therapy for Psychosocial Issues
(Group PM+ Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a group program called Rare Group Problem Management Plus, designed to help parents or guardians of children with rare conditions manage stress and other practical challenges. The program includes five weekly sessions, each lasting 90 minutes, focusing on topics like stress management and building social support. Conducted via telemedicine, participants will need a smartphone or tablet. This trial suits English or Spanish-speaking caregivers who feel distressed and care for a child with a rare disease. As an unphased trial, it offers caregivers a unique opportunity to access supportive resources tailored to their needs.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on group therapy and does not involve medication changes.
What prior data suggests that this group therapy is safe for participants?
Research has shown that Problem Management Plus (PM+) is safe for use in different communities. PM+ is a program designed to help people manage stress and emotional problems. No serious side effects have been reported. In fact, studies have found that PM+ effectively reduces distress and anxiety over time. This program has been successfully used in various situations, such as with Syrian refugees, and many participants have continued to engage with it. While the specific version called Rare Group PM Plus is new, the overall method has a history of being well-received.12345
Why are researchers excited about this trial?
Researchers are excited about Rare Group PM Plus because it offers a fresh approach to dealing with psychosocial issues through a structured group therapy format. Unlike traditional individual therapy or medication, this treatment involves five weekly group sessions, each focusing on different aspects like stress management, problem-solving, and enhancing social support. The group setting not only provides peer support but also encourages participants to actively engage and learn from each other's experiences, potentially leading to more lasting and meaningful improvements in mental well-being. This innovative approach has the potential to fill a gap in the current standard of care, which often doesn't emphasize the social and communal aspects of healing.
What evidence suggests that Rare Group PM Plus is effective for psychosocial issues?
Research has shown that the Rare Group Problem Management Plus (PM+) program, which participants in this trial will receive, helps people manage psychological distress. Studies have found that Group PM+ can improve physical health and reduce negative feelings like stress, anxiety, and depression. One study found it effective in easing symptoms of common mental health issues among Syrian refugees. The program focuses on managing stress, solving problems, and boosting social support. While researchers are still studying the specific effects for parents of children with rare conditions, positive results in other groups suggest it could be helpful.12367
Who Is on the Research Team?
Maureen Lyon, PhD
Principal Investigator
Children's National Research Institute
Are You a Good Fit for This Trial?
This trial is for parents or guardians of children aged 1 to 17 with a rare condition. They should be able to attend weekly group sessions via telemedicine using a smartphone or tablet, which the study team can assist in providing if necessary.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Assessment
Participants complete assessments before starting the Rare Group PM+ intervention
Treatment
Participants undergo the Rare Group PM+ intervention, consisting of 5 weekly sessions
Follow-up
Participants complete assessments within 2 weeks after completing the Rare Group PM+ intervention
What Are the Treatments Tested in This Trial?
Interventions
- Rare Group Problem Management Plus
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's National Research Institute
Lead Sponsor
Travere Therapeutics, Inc.
Industry Sponsor